Format

Send to

Choose Destination
Semin Nephrol. 2013 Nov;33(6):508-30. doi: 10.1016/j.semnephrol.2013.08.003.

Atypical hemolytic uremic syndrome.

Author information

1
The Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK. Electronic address: david.kavanagh@ncl.ac.uk.

Abstract

Hemolytic uremic syndrome (HUS) is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. The atypical form of HUS is a disease characterized by complement overactivation. Inherited defects in complement genes and acquired autoantibodies against complement regulatory proteins have been described. Incomplete penetrance of mutations in all predisposing genes is reported, suggesting that a precipitating event or trigger is required to unmask the complement regulatory deficiency. The underlying genetic defect predicts the prognosis both in native kidneys and after renal transplantation. The successful trials of the complement inhibitor eculizumab in the treatment of atypical HUS will revolutionize disease management.

KEYWORDS:

Complement; eculizumab; factor H; factor I; hemolytic uremic syndrome; membrane cofactor protein; thrombomodulin; transplantation

PMID:
24161037
PMCID:
PMC3863953
DOI:
10.1016/j.semnephrol.2013.08.003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center